EXP3174, a metabolite of losartan (MK954, DuP753) is more potent than losartan in blocking the angiotensin ll-induced responses in vascular smooth muscle cells-Reference-Cited by-同舟云学术

EXP3174, a metabolite of losartan (MK954, DuP753) is more potent than losartan in blocking the angiotensin ll-induced responses in vascular smooth muscle cells

Published:1993-02 Issue:2 Volume:11 Page:155-162
ISSN:0263-6352
Container-title:Journal of Hypertension
language:en
Short-container-title:Journal of Hypertension

Author:

Sachinidis Agapios,Ko Yon,Weisser Peter,zu BricBkwedde Maria-Katharina Meyer,D??sing Rainer,Christian Roger,Wieczorek Andreas J.,Vetter Hans

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protective effect of novel angiotensin receptor neprilysin inhibitor S086 on target organ injury in spontaneously hypertensive rats;Biomedicine & Pharmacotherapy;2024-01

2. Changes in Pharmacokinetics and Pharmacodynamics of Losartan in Experimental Diseased Rats Treated with Curcuma longa and Lepidium sativum;Pharmaceuticals;2022-12-26

3. Serum Concentrations of Losartan Metabolites Correlate With Improved Physical Function in a Pilot Study of Prefrail Older Adults;The Journals of Gerontology: Series A;2022-05-04

4. Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling;Journal of Pharmacokinetics and Pharmacodynamics;2022-01-21

5. A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers;Expert Opinion on Investigational Drugs;2021-11-08